ST. ALBANS, England--(BUSINESS WIRE)--ARC International (LSE:ARK) today announced that CVRx®, Inc. has chosen a member of the configurable ARC® 600 core family to drive its Rheos™ Baroreflex Hypertension Therapy™ System. CVRx chose a configurable ARC core because of its very small size, ability to operate using extremely low power, and long-term reliability – all key criteria for “deeply embedded” organic applications. This news release complements ARC’s announcement of the adoption of its configurable solutions by 11 companies in North America. See companion announcement dated July 11, 2007 for more details.
